General Information of This Drug (ID: DMSRJY3)

Drug Name
Saredutant   DMSRJY3
Synonyms
SR-48968; 142001-63-6; SR 48968; SR48968; UNII-720U2QK8I5; (S)-N-Methyl-N(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl)benzamide; CHEMBL308148; SR48968C; 720U2QK8I5; N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide; N-((S)-beta-(2-(4-Acetamido-4-phenylpiperidino)ethyl)-3,4-dichlorophenethyl)-N-methylbenzamide; [3H]saredutant; SR 48968C; Benzamide, N-((2S)-4-(4-(acetylamino)-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl)-N-methyl-; SR 48965; SR-48965; SR-489686; SR-48968C
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Discontinued in Phase 3 [1]
Depression 6A70-6A7Z Discontinued in Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Escitalopram + Saredutant DC8Z2DS Escitalopram Major Depressive Disorder [2]
Paroxetine + Saredutant DCNVROM Paroxetine Depressive Disorder, Major [3]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2111).
2 ClinicalTrials.gov (NCT00531622) An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
3 ClinicalTrials.gov (NCT00629551) An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder